Enveda
What they do & why Kinnevik is invested
Enveda is revolutionizing drug discovery by tapping into the vast potential of life’s chemical diversity. Using its AI-driven search engine, the company decodes and maps the complex chemistry found in living systems, unlocking an untapped dark chemical space and discovering novel drug candidates.
Founded by molecular biologist Viswa Colluru – formerly of Recursion, another Kinnevik company (glance to your right) – Enveda was built on the belief that nature holds answers to many diseases. Though some of the most successful drugs in human history came from plants, nature-inspired drug discovery declined because of the slow, inefficient, and difficult process of interpreting plant chemistry. Enveda overcomes this through its proprietary platform built around mass spectrometry, machine learning, and advanced robotics.
In just five years, Enveda’s platform has generated 14 development candidates, six assets in IND (Investigational New Drug)-enabling studies, and three clinical assets. Over the next 1-2 years, Enveda is dedicated to advancing key programs in atopic dermatitis, asthma, obesity, and metabolic diseases to critical value-inflection milestones, partnering select programs to unlock near-term value through strategic business development.
Kinnevik is attracted by Enveda’s innovative approach to drug discovery and its potential to redefine health. By combining novel AI with deep scientific expertise, Enveda addresses longstanding challenges in uncovering effective treatments, positioning itself as a highly promising player in the sector.
Key information
- Clinical-stage biotech company pioneering small molecule drug discovery inspired from life’s chemistry
- Leverages mass spectrometry, robotics, and advanced machine-learning techniques to map life’s chemistry and uncover noveltherapeutics - 4x faster and at 1/10 of the cost compared to the industry average
- Focused on advancing novel drugs to criticalvalue-inflection milestones through internal development, retaining optionality of partnering out selective programs
News in the quarter
- Initiated Phase 2a trials for its leading drugcandidate targeting atopic dermatitis and asthma, a key milestone that follows stronginterim Phase 1b results. A global Phase 2bstudy is planned for 2026
- Advanced two new assets to Phase 1 trials, aonce-daily oral therapy designed for chronic weight management, and an oral therapy treating inflammatory bowel disease. Envedanow has three assets in the clinic, validatingits platform’s ability to discover new therapies at speed
